nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

30.08.2022 | Research

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

verfasst von: Sena Valcarcel, Javier Gallego, Paula Jimenez-Fonseca, Marc Diez, Eva Martínez de Castro, Raquel Hernandez, Virginia Arrazubi, Ana Custodio, Juana María Cano, Ana Fernández Montes, Ismael Macias, Laura Visa, Aitana Calvo, Rosario Vidal Tocino, Nieves Martínez Lago, María Luisa Limón, Mónica Granja, Mireia Gil, Paola Pimentel, Lola Macia-Rivas, Carolina Hernández Pérez, Montserrat Mangas, Alfonso Martín Carnicero, Paula Cerdà, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Mª Dolores Mediano Rambla, Marta Martin Richard, Alberto Carmona-Bayonas

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to compare ramucirumab-paclitaxel versus chemotherapy in second-line (2L) advanced gastroesophageal cancer (aGEC) based on HER2 status and analyze prognostic factors.

Methods

The study includes patients from the AGAMENON-SEOM registry with aGEC and known HER2 status who received 2L between 2016 and 2021. The Kaplan–Meier method was used to calculate progression-free survival (PFS) and overall survival (OS) and multivariable Cox regression analysis was done to adjust for confounding variables.

Results

Of the 552 patients who met the selection criteria, 149 (26.9%) had HER2-positive aGEC, 89 were treated with chemotherapy, and 60 with ramucirumab-paclitaxel, and 403 had an HER2-negative aGEC, 259 were treated with chemotherapy, and 144 with ramucirumab-paclitaxel.

In the whole sample, 2L PFS was 3.0 months (95% CI 2.8–3.2), 2L OS, 5.7 months (5.2–6.3), and ramucirumab-paclitaxel versus chemotherapy was associated with increased PFS (HR 0.64, 95% CI 0.53–0.78, p < 0.0001) and OS (HR 0.68, 0.55–0.83, p = 0.0002). Median PFS of ramucirumab- paclitaxel versus chemotherapy was 3.5 vs 2.8 months (HR 0.67, 0.54–0.83, p = 0.0004) in HER2-negative, and 4.7 vs 2.7 months (HR 0.57, 0.40–0.82, p = 0.0031) in HER2-positive aGEC, respectively. Median OS for ramucirumab-paclitaxel versus chemotherapy was 6.6 vs 5 months (HR 0.67, 0.53–0.85, p = 0.0007) in HER2-negative, and 7.4 vs 5.6 months (HR 0.70, 0.53–1.04, p = 0.083) in HER2-positive aGEC, respectively. ECOG-PS, tumor burden, Lauren subtype, and neutrophil–lymphocyte ratio were prognostic factors.

Conclusions

In patients with an aGEC from the AGAMENON-SEOM registry, 2L treatment with ramucirumab-paclitaxel was superior to chemotherapy in PFS, OS and response rate, independent of HER2 status.

Nur mit Berechtigung zugänglich

Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A et al (2021) Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer 24:926–936. https://doi.org/10.1007/s10120-021-01169-6CrossRefPubMed

Bang Y-J, van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-XCrossRefPubMed

Bartsch R, Wenzel C, Altorjai G et al (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853–3858. https://doi.org/10.1200/JCO.2007.11.9776CrossRefPubMed

Bürkner P-C (2017) brms: an R package for bayesian multilevel models using Stan. J Stat Softw. https://doi.org/10.18637/jss.v080.i01

Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS et al (2016) On the effect of triplet or doublet chemotherapy in advanced gastric cancer: results from a national cancer registry. J Natl Compr Canc Netw 14:1379–1388. https://doi.org/10.6004/jnccn.2016.0148CrossRefPubMed

Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A et al (2018a) Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer 21:96–105. https://doi.org/10.1007/s10120-017-0718-5CrossRefPubMed

Carmona-Bayonas A, Jiménez-Fonseca P, Echavarria I et al (2018b) Surgery for metastases for esophageal-gastric cancer in the real world: data from the AGAMENON national registry. Eur J Surg Oncol 44:1191–1198. https://doi.org/10.1016/j.ejso.2018.03.019CrossRefPubMed

Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M et al (2019) Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer. Thromb Haemost 119:1849–1859. https://doi.org/10.1055/s-0039-1694012CrossRefPubMed

Carmona-Bayonas A, Jiménez-Fonseca P, Gallego J, Msaouel P (2022) Causal considerations can inform the interpretation of surprising associations in medical registries. Cancer Invest 40:1–13. https://doi.org/10.1080/07357907.2021.1999971CrossRefPubMed

Choi IS, Kim JH, Lee JH et al (2018) A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: a nationwide health insurance database study. PLoS ONE 13:e0205853. https://doi.org/10.1371/journal.pone.0205853CrossRefPubMedPubMedCentral

Cohen DJ, Tabernero J, van Cutsem E et al (2022) A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. J Clin Oncol 40:TPS369–TPS369. https://doi.org/10.1200/JCO.2022.40.4_suppl.TPS369CrossRef

Cotes Sanchís A, Gallego J, Hernandez R et al (2020) Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry. PLoS ONE 15:e0235848. https://doi.org/10.1371/journal.pone.0235848CrossRefPubMedPubMedCentral

Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P et al (2017) Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. Br J Cancer 116:1526–1535. https://doi.org/10.1038/bjc.2017.122CrossRefPubMedPubMedCentral

Van Cutsem E, Di Bartolomeo E, Smyth E (2021) Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen

de Vita F, Borg C, Farina G et al (2019) Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol 15:2723–2731. https://doi.org/10.2217/fon-2019-0243CrossRefPubMed

di Bartolomeo M, Niger M, Tirino G et al (2018) Ramucirumab as second-line therapy in metastatic gastric cancer: real-world data from the RAMoss study. Target Oncol 13:227–234. https://doi.org/10.1007/s11523-018-0562-5CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210CrossRefPubMed

Ford HER, Marshall A, Bridgewater JA et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78–86. https://doi.org/10.1016/S1470-2045(13)70549-7CrossRefPubMed

Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39. https://doi.org/10.1016/S0140-6736(13)61719-5CrossRefPubMed

Harrel FE (2022) Jr Package ‘rms’. http://cran.r-project.org/web/packages/rms/index.html. Accessed 8 May 202

Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, Phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438–4444. https://doi.org/10.1200/JCO.2012.48.5805CrossRefPubMed

Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2CrossRefPubMedPubMedCentral

Jiménez Fonseca P, Carmona-Bayonas A, Hernández R et al (2017) Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. Br J Cancer 117:775–782. https://doi.org/10.1038/bjc.2017.245CrossRefPubMedPubMedCentral

Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML et al (2017) Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer 20:465–474. https://doi.org/10.1007/s10120-016-0639-8CrossRefPubMed

Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E et al (2021a) External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Gastric Cancer 24:445–456. https://doi.org/10.1007/s10120-020-01116-xCrossRefPubMed

Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A et al (2021b) External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Ther Adv Med Oncol 13:175883592110196. https://doi.org/10.1177/17588359211019672CrossRef

Jung M, Ryu M-H, Oh DY et al (2018) Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21:819–830. https://doi.org/10.1007/s10120-018-0806-1CrossRefPubMed

Kang JH, Lee il S, Lim DH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized Phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518. https://doi.org/10.1200/JCO.2011.39.4585CrossRefPubMed

Kang Y-K, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471. https://doi.org/10.1016/S0140-6736(17)31827-5CrossRefPubMed

Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB et al (2021) Outcomes on <scp>anti-VEGFR</scp> -2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int J Cancer 149:378–386. https://doi.org/10.1002/ijc.33559CrossRefPubMed

Kim J, Bowlby R, Mungall A et al (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541:169–175. https://doi.org/10.1038/nature20805CrossRef

Kim BJ, Jee H-J, Rha SY et al (2022) Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). Gastric Cancer 25:609–618. https://doi.org/10.1007/s10120-021-01276-4CrossRefPubMed

Kojima T, Shah MA, Muro K et al (2020) Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38:4138–4148. https://doi.org/10.1200/JCO.20.01888CrossRefPubMed

Lee K-W, Maeng CH, Kim T-Y et al (2019) A phase iii study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist 24:18-e24. https://doi.org/10.1634/theoncologist.2018-0142CrossRefPubMed

Longo F, Jorge M, Yaya R et al (2021) Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study. Future Oncol 17:1777–1791. https://doi.org/10.2217/fon-2020-1216CrossRefPubMed

Martín-Richard M, Carmona-Bayonas A, AnaB C et al (2020) SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 22:236–244. https://doi.org/10.1007/s12094-019-02259-9CrossRefPubMed

Muro K, van Cutsem E, Narita Y et al (2019) Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 30:19–33. https://doi.org/10.1093/annonc/mdy502CrossRefPubMed

Okines AFC, Asghar U, Cunningham D et al (2010) Rechallenge with platinum plus fluoropyrimidine +/– epirubicin in patients with oesophagogastric cancer. Oncology 79:150–158. https://doi.org/10.1159/000322114CrossRefPubMed

Palle J, Tougeron D, Pozet A et al (2017) Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. Oncotarget 8:101383–101393. https://doi.org/10.18632/oncotarget.20711CrossRefPubMedPubMedCentral

Paulson AS, Hess LM, Liepa AM et al (2018) Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer 21:831–844. https://doi.org/10.1007/s10120-018-0796-zCrossRefPubMed

Sasaki A, Kawazoe A, Eto T et al (2020) Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open 5:e000775. https://doi.org/10.1136/esmoopen-2020-000775CrossRefPubMedCentral

Satoh T, Xu R-H, Chung HC et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2 -amplified advanced gastric cancer in Asian Populations: TyTAN—a randomized, Phase III study. J Clin Oncol 32:2039–2049. https://doi.org/10.1200/JCO.2013.53.6136CrossRefPubMed

Shitara K, Doi T, Dvorkin M et al (2018a) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19:1437–1448. https://doi.org/10.1016/S1470-2045(18)30739-3CrossRefPubMed

Shitara K, Özgüroğlu M, Bang Y-J et al (2018b) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392:123–133. https://doi.org/10.1016/S0140-6736(18)31257-1CrossRefPubMed

Shitara K, Seraj J, Franke FA et al (2021) 1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): a randomized phase III study. Ann Oncol 32:S1073. https://doi.org/10.1016/j.annonc.2021.08.1545CrossRef

Smyth EC, Verheij M, Allum W et al (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v38–v49. https://doi.org/10.1093/annonc/mdw350CrossRefPubMed

Team R. C. (2022) R: A Language and Environment for Statistical Computing, Reference Index, R Foundation for Statistical Computing. http://cran.r-project. org/doc/manuals/r-release/fullrefman. pdf. Accessed 8 May 2022

Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306–2314. https://doi.org/10.1016/j.ejca.2011.06.002CrossRefPubMed

Thuss-Patience PC, Shah MA, Ohtsu A et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18:640–653. https://doi.org/10.1016/S1470-2045(17)30111-0CrossRefPubMed

Visa L, Jiménez-Fonseca P, Martínez EA et al (2018) Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: a real-world data, non-inferiority analysis. J Geriatric Oncol 9:254–264. https://doi.org/10.1016/j.jgo.2017.11.008CrossRef

von Minckwitz G, du Bois A, Schmidt M et al (2009) trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol 27:1999–2006. https://doi.org/10.1200/JCO.2008.19.6618CrossRef

Wagner AD, Syn NL, Moehler M et al (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004064.pub4CrossRefPubMedPubMedCentral

Wilke H, Muro K, van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6CrossRefPubMed

Yamada Y, Boku N, Mizusawa J et al (2019) Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4:501–510. https://doi.org/10.1016/S2468-1253(19)30083-4CrossRefPubMed

Zaragoza-Huesca D, Garrido-Rodríguez P, Jiménez-Fonseca P et al (2022) Identification of thrombosis-related genes in patients with advanced gastric cancer: data from AGAMENON-SEOM Registry. Biomedicines 10:148. https://doi.org/10.3390/biomedicines10010148CrossRefPubMedPubMedCentral

Titel: Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
verfasst von: Sena Valcarcel
Javier Gallego
Paula Jimenez-Fonseca
Marc Diez
Eva Martínez de Castro
Raquel Hernandez
Virginia Arrazubi
Ana Custodio
Juana María Cano
Ana Fernández Montes
Ismael Macias
Laura Visa
Aitana Calvo
Rosario Vidal Tocino
Nieves Martínez Lago
María Luisa Limón
Mónica Granja
Mireia Gil
Paola Pimentel
Lola Macia-Rivas
Carolina Hernández Pérez
Montserrat Mangas
Alfonso Martín Carnicero
Paula Cerdà
Lucía Gomez Gonzalez
Francisco Garcia Navalon
Mª Dolores Mediano Rambla
Marta Martin Richard
Alberto Carmona-Bayonas
Publikationsdatum: 30.08.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-022-04294-6

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2023

FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy

The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition

Anticancer bioactivity of zerumbone on pediatric rhabdomyosarcoma cells

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes